EP Patent
EP3454835B1 — Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof
Assigned to AstraZeneca AB · Expires 2021-03-31 · 5y expired
What this patent protects
Patent listed against Onpattro.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.